|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500105968 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-15 11:30:52 |
|
注册时间: Date of Registration: |
2025-07-15 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国青少年型复发性呼吸道乳头状瘤病和成人型复发性呼吸道乳头状瘤病患者的疾病负担-BREATH China |
|
Public title: |
The Burden of Recurrent REspiratory PApillomatosis in AdulTs and CHildren: The BREATH Study in China |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中国青少年型复发性呼吸道乳头状瘤病和成人型复发性呼吸道乳头状瘤病患者的疾病负担-BREATH China |
|
Scientific title: |
The Burden of Recurrent REspiratory PApillomatosis in AdulTs and CHildren: The BREATH Study in China |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
胡尚英 |
研究负责人: |
赵方辉 |
|
Applicant: |
Shangying Hu |
Study leader: |
Fanghui Zhao |
|
申请注册联系人电话: Applicant telephone: |
+86 137 0108 8505 |
研究负责人电话: Study leader's telephone: |
+86 158 0156 5892 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
shangyinghu@cicams.ac.cn |
研究负责人电子邮件: Study leader's E-mail: |
zhaofangh@cicams.ac.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市朝阳区潘家园南里17号肿瘤医院 |
研究负责人通讯地址: |
北京市朝阳区潘家园南里17号肿瘤医院 |
|
Applicant address: |
No.17 Pan-jia-yuan South Lane, Chaoyang District, Beijing |
Study leader's address: |
No.17 Pan-jia-yuan South Lane, Chaoyang District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
100021 |
研究负责人邮政编码: Study leader's postcode: |
100021 |
|
申请人所在单位: |
中国医学科学院肿瘤医院 |
||
|
Applicant's institution: |
Cancer Hospital, Chinese Academy of Medical Sciences |
||
|
研究负责人所在单位: |
中国医学科学院肿瘤医院 |
||
|
Affiliation of the Leader: |
Cancer Hospital, Chinese Academy of Medical Sciences |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
24/658-4938 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
国家癌症中心/中国医学科学院北京协和医学院肿瘤医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethic Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-01-02 00:00:00 |
||
|
伦理委员会联系人: |
吴大维 |
||
|
Contact Name of the ethic committee: |
Dawei Wu |
||
|
伦理委员会联系地址: |
北京市朝阳区潘家园南里17号 |
||
|
Contact Address of the ethic committee: |
No.17 Pan-jia-yuan South Lane, Chaoyang District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 8778 8495 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国医学科学院肿瘤医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Cancer Hospital, Chinese Academy of Medical Sciences |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市朝阳区潘家园南里17号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.17 Pan-jia-yuan South Lane, Chaoyang District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
Target disease: |
Recurrent respiratory papillomatosis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
主要目的:描述在研究期内,各分中心医院每年接诊治疗的青少年型复发性呼吸道乳头状瘤病(Juvenile-onset recurrent respiratory papillomatosis, JoRRP)和成人型复发性呼吸道乳头状瘤病(Adult-onset recurrent respiratory papillomatosis, AoRRP)病例数及总数,分析JoRRP患者和AoRRP患者的人口统计学特征及临床特征,以了解该病在不同年龄、地区的流行病学特征、疾病诊疗特点、复发和预后情况,以及随时间的变化趋势等。 次要目的:评估中国JoRRP和AoRRP患者的人乳头瘤病毒(HPV)基因型分布情况。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary objectives: to describe the number and total number of juvenile-onset recurrent respiratory papillomasis (JoRRP) and adult-onset recurrent respiratory papillomasis (AoRRP) cases treated in each sub-central hospital every year during the study period, and to analyze the demographic and clinical characteristics of JoRRP and AoRRP patients, so as to understand the epidemiological characteristics, disease diagnosis and treatment characteristics, recurrence and prognosis of the disease in different ages and regions, as well as the change trend over time. Secondary objectives: To evaluate the distribution of human papillomavirus (HPV) genotypes in Chinese patients with JORRP and AoRRP. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 针对主要目的,纳入研究期内所有病理诊断为RRP的患者。 2. 针对次要目的,纳入在研究期内符合以下标准的患者样本: (1)病理诊断为RRP;(2)在既往手术中留存了病理组织蜡块/肿瘤组织,并能提供进行HPV基因分型检测。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. For the primary objective, all patients with pathological diagnosis of RRP during the study period will be included. 2. For the secondary objective, patient samples meeting the following criteria during the study period will be included: (1) Pathological diagnosis of RRP; (2) The pathological tissue wax block / tumor tissue was preserved in the previous surgical procedure, and it can be provided for HPV genotyping testing. |
||||||||||||||||||||||
|
排除标准: |
1. 针对次要目的: 根据实验室的标准,现有组织样本质量较低,无法对组织病理学和HPV感染状态进行适当评估 (例如组织块质量不佳、太薄或被判定为保存不当)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. For the secondary objective: according to the standards of the laboratory, the quality of the tissue samples is low, and the histopathology and HPV infection status cannot be properly evaluated (for example, the tissue block is of poor quality, too thin, or considered to be improperly preserved). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-15 00:00:00至 To 2026-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-07-15 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1.数据采集:本研究据数据来自每位入组患者的电子病历记录,其中包括个人基本信息、与RRP相关的诊断及临床特征信息、治疗及预后情况。 2、数据管理:纸质资料存放于指定位置并配锁,钥匙由现场负责人与数据管理员保管:电子资料录入redcap电子数据库,进行保存核查与整理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1. Data collection: the data of this study are from the electronic or paper medical record of each patient, including basic personal information, diagnosis and clinical characteristics related to RRP, treatment and prognosis information. 2. Data management: the paper data is stored in the designated location and equipped with a lock, and the key is kept by the on-site person in charge and the data manager: the electronic data is entered into the redcap electronic database for preservation, verification and sorting. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |